Anavex Life Sciences Corp (AVXL)

[boi568]

Doc notwithstanding, I do not see CTAD accepting a late breaking presentation on Parkinson's patients that is without relevance to its Alzheimer's audience. Just that fact -- let alone the positive Anavex PR -- takes this out of the negative and mediocre categories. It is not news to anyone, ordinarily, that a Phase 2 trial in one disease has no significance in another disease; that would not be presented. It is big news if the opposite is true, and that is the scenario here.

BTW, there has been a documented history in AD that anyone proposing a non-amyloid plaque theory is not heard. We are being heard. I think the old AD thinking has finally died and there is some openness to new ideas. But I also think this presentation will be difficult for many in the audience to absorb. I would expect a great deal of legitimately skeptical questioning.